Aug 10, 2021 7:00 am EDT Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME
May 20, 2021 7:00 am EDT Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs
May 18, 2021 7:00 am EDT Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board
May 17, 2021 4:05 pm EDT Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress
May 4, 2021 8:00 am EDT Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema
